337 results on '"Rotunno, Giada"'
Search Results
2. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
3. Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
4. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
5. CALR mutation burden in essential thrombocythemia and disease outcome
6. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis
7. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
8. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
9. Targeted deep sequencing in polycythemia vera and essential thrombocythemia
10. Validation of the Mayo alliance prognostic system for mastocytosis
11. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
12. Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
13. Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing
14. Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
15. Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis
16. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
17. Clonal dynamics and copy number variants by single‐cell analysis in leukemic evolution of myeloproliferative neoplasms.
18. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
19. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
20. Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation
21. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms
22. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
23. ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
24. SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates
25. Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
26. A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis
27. Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis
28. Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms
29. Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class
30. The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA-Mutated Acute Myeloid Leukemia
31. Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome
32. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms
33. Lenalidomide: A double‐edged sword for concomitant multiple myeloma and post‐essential thrombocythemia myelofibrosis
34. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
35. Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis
36. BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma
37. Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation
38. A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease
39. Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms
40. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
41. Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
42. Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis
43. Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics
44. Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)
45. Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
46. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
47. Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis
48. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
49. Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study
50. Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.